

Figure S1 The association between the *EGFR* mutation type and DFS. (A) DFS among patients with different *EGFR* mutations; (B) DFS among the MIP/SOL patients with different *EGFR* mutations; (C) DFS among the non-MIP/SOL patients with different *EGFR* mutations. DFS, disease-free survival; *EGFR*, epidermal growth factor receptor; MIP/SOL, micropapillary/solid.




Figure S2 The association between adjuvant therapy and DFS in the patients with different *EGFR* status types. *EGFR*, epidermal growth factor receptor; DFS, disease-free survival; TKI, tyrosine kinase inhibitor.




Figure S3 The survival difference between patients with and without adjuvant therapy in high-risk (A) and high-risk MIP/SOL group (B). DFS, disease-free survival; MIP/SOL, micropapillary/solid.